Obesity, Iron Regulation and Colorectal Cancer Risk
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Colorectal Cancer, Colitis, Obesity Weight Loss, Nephrology |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Nephrology / Urology, Oncology |
| Healthy: | No |
| Age Range: | 55 - 70 |
| Updated: | 10/7/2018 |
| Start Date: | July 15, 2015 |
| End Date: | June 30, 2019 |
Obesity is an independent risk factor for colorectal cancer (CRC) although the underlying
mechanisms have not been elucidated. Dietary nutrients play a key role in both the prevention
and promotion of CRC. While iron is an essential nutrient, excess iron is associated with
carcinogenesis. Unlike the systemic compartment, the intestinal lumen lacks an efficient
system to regulate iron. In conditions when dietary iron malabsorption and intestinal
inflammation co-exist, greater luminal iron is associated with increased intestinal
inflammation and a shift in the gut microbiota to more pro-inflammatory strains. However,
treatments designed to reduce luminal, including diet restriction and chelation, are
associated with lower intestinal inflammation and the colonization of protective gut
microbes. Obesity is associated with inflammation-induced, hepcidin-mediated, iron metabolism
dysfunction characterized by iron deficiency and dietary iron malabsorption. Obesity is also
linked to intestinal inflammation. Currently, there is a fundamental gap in understanding how
altered iron metabolism impacts CRC risk in obesity.
The investigator's objective is to conduct a crossover controlled feeding trial of: 1) a
"Typical American" diet with "high" heme/non-heme iron", 2) a "Typical American" diet with
"low" iron, and 3) a Mediterranean diet with "high" non heme iron and examine effects on
colonic and systemic inflammation and the gut microbiome.
mechanisms have not been elucidated. Dietary nutrients play a key role in both the prevention
and promotion of CRC. While iron is an essential nutrient, excess iron is associated with
carcinogenesis. Unlike the systemic compartment, the intestinal lumen lacks an efficient
system to regulate iron. In conditions when dietary iron malabsorption and intestinal
inflammation co-exist, greater luminal iron is associated with increased intestinal
inflammation and a shift in the gut microbiota to more pro-inflammatory strains. However,
treatments designed to reduce luminal, including diet restriction and chelation, are
associated with lower intestinal inflammation and the colonization of protective gut
microbes. Obesity is associated with inflammation-induced, hepcidin-mediated, iron metabolism
dysfunction characterized by iron deficiency and dietary iron malabsorption. Obesity is also
linked to intestinal inflammation. Currently, there is a fundamental gap in understanding how
altered iron metabolism impacts CRC risk in obesity.
The investigator's objective is to conduct a crossover controlled feeding trial of: 1) a
"Typical American" diet with "high" heme/non-heme iron", 2) a "Typical American" diet with
"low" iron, and 3) a Mediterranean diet with "high" non heme iron and examine effects on
colonic and systemic inflammation and the gut microbiome.
Inclusion Criteria:
- Self-identify as Hispanic, African American, or Caucasian.
- Meet body mass index (BMI > = 30.0 kg/m2) and C-reactive protein (CRP) criteria (> 2.0
mg/dl)
- Post-menopausal (no menstruation in the past 12 months)
- Weight stable (< 3% weight change in the past 3 months)
- Non-smoker
- No major medical problems
- Have a working phone
- No known allergies, intolerance, medical, secular or religious dietary restrictions
Exclusion Criteria:
- Chronic constipation (less than three stools per week for several months)
- History or intestinal cancer, inflammatory bowel disease, celiac disease, or
malabsorptive bariatric surgery
- Previous intestinal surgery
- H pylori infection or taking H2 blockers (e.g., Zantac, Pepcid) /antacids (e.g.,
Rolaids) more than 3 times per week
- Significant blood loss or blood donation in past 3 months
- Active gastrointestinal bleed
- Any surgery in the past 3 months
- Hemochromatosis
- Sickle cell disease
- Hereditary polyposis
- Rheumatoid arthritis
- Type I or Type II diabetes
- Smoker
- Antibiotic use in the past 2 months
- Excessive alcohol consumption [> 2 standard alcoholic drinks (12 ounces of beer, 5
ounces of wine, 1 shot of hard liquor) per day]
- Aspirin use >81 mg/day OR >325 mg/every other day
- Regularly taking probiotics, fiber supplements, Orlistat (over the counter brand name:
Alli), or steroids (inhaled or oral)
We found this trial at
1
site
2035 W Taylor St
Chicago, Illinois
Chicago, Illinois
(312) 996-4350
Phone: 312-355-5521
University of Illinois at Chicago A major research university in the heart of one of...
Click here to add this to my saved trials
